{
  "docId": "019de076-cd1b-731e-ae5e-e1dc823ccd70",
  "docSlug": "8f301a1a54ee099c965687c909e40052",
  "documentTitle": "Equillium | Investor Presentation Deck | 40 slides",
  "authorId": "equillium",
  "authorName": "Equillium",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 40,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses a structured comparison of four distinct disease areas to justify the market potential of the EQ101 franchise.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-cd1b-731e-ae5e-e1dc823ccd70/18",
  "deckHref": "/decks/019de076-cd1b-731e-ae5e-e1dc823ccd70",
  "deckJsonHref": "/decks/019de076-cd1b-731e-ae5e-e1dc823ccd70.json",
  "deckAnchorHref": "/decks/019de076-cd1b-731e-ae5e-e1dc823ccd70#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.115,
        "w": 0.928,
        "x": 0.036,
        "y": 0.175
      },
      "kind": "callout",
      "text": "Multi-Billion dollar market opportunity for EQ101 in medical dermatology. Large need exists for safe and effective therapies",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c746532f-397a-4c98-acc8-a98fa251643a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.21,
        "x": 0.265,
        "y": 0.35
      },
      "kind": "list",
      "text": "Alopecia Areata: 250,000 US moderate-severe Patients; Phase 2 Study ongoing; Only two FDA approvals: JAKi; Late-stage Industry pipeline predominantly JAKi",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0ca97387-73f9-4b3a-9114-320f6c4799e1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.21,
        "x": 0.036,
        "y": 0.35
      },
      "kind": "list",
      "text": "Cutaneous T cell Lymphoma: 24,000 adult US Patients; PoC Achieved, Phase 2/3 Ready, Open IND; Unmet need for safe and effective therapies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4e872cc3-6ebb-436e-a03e-9a679ecac866",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.21,
        "x": 0.52,
        "y": 0.35
      },
      "kind": "list",
      "text": "Vitiligo: 1.5M+ US Patients; Future Opportunity; Only one FDA approval: JAKi; Late-stage Industry pipeline predominantly JAKi",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "89847088-dd3f-4d6b-88e2-419b36c8a233",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.21,
        "x": 0.775,
        "y": 0.35
      },
      "kind": "list",
      "text": "Atopic Dermatitis: 6.6M US moderate-severe Patients; Future Opportunity; 3 FDA approved JAKi; Large refractory population in need of safe treatment alternatives",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d117e2d9-0542-416b-8869-e95f6539f773",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.58,
        "x": 0.125,
        "y": 0.945
      },
      "kind": "source-note",
      "text": "1) Kx Advisors 2) Benigno, Clin Cosmet Investig Dermatol, 2020 3) Bergqvist C, Ezzedine K. Vitiligo: A Review. Dermatology. 2020 4) Chiesa Fuxench ZC, J Invest Dermatol. 2019",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c0a888c-87e8-427b-b8df-46bb109d9c34",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.713,
        "x": 0.036,
        "y": 0.075
      },
      "kind": "title",
      "text": "EQ101: Valuable Medical Dermatology Franchise",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c994e47a-0284-4242-a937-c2048fb53222",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Market Segmentation Pyramid",
      "slug": "market-segmentation-pyramid",
      "agent": null,
      "layer": "slide",
      "matchId": "23081ba7-12bb-444a-9ff0-dd9a088e1225",
      "evidence": "list/bullet: Atopic Dermatitis: 6.6M US moderate-severe Patients; Future Opportunity; 3 FDA approved JAKi; Large refractory population in need of safe treatment alternatives",
      "confidence": 0.6
    }
  ],
  "frameworks": [
    {
      "name": "market-segmentation-pyramid",
      "slug": null,
      "matchId": "35827eb6-8329-4e40-a3e0-464331e30f18",
      "evidence": "The slide segments the total addressable market into four distinct clinical indications with specific patient counts.",
      "confidence": 0.7
    }
  ],
  "arcBeats": [
    {
      "to": 18,
      "from": 18,
      "beatId": "56d95f6f-f945-4651-9b21-af3472935781",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "Market sizing is presented on page 18",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}